An Open-Label Extension, Multi-Centered, Phase 2 Trial to Describe the Safety and Efficacy of TEV-56286 (Emrusolmin) in Participants with Multiple System Atrophy"
Clinical Trial Grant
Administered By
Neurology, Movement Disorders
Awarded By
Teva Branded Pharmaceutical Products R&D, Inc
Start Date
February 19, 2026
End Date
December 31, 2029
Administered By
Neurology, Movement Disorders
Awarded By
Teva Branded Pharmaceutical Products R&D, Inc
Start Date
February 19, 2026
End Date
December 31, 2029